CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the Leerink Partners Rare Disease Roundtable at 1:05 PM ET on September 28, in New York, NY.
A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing novel
medicines to transform the lives of patients with life-altering central
nervous system (CNS) disorders. Sage has a portfolio of novel product
candidates targeting critical CNS receptor systems, GABA and NMDA.
Sage's lead program, SAGE-547, is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure disorder,
and is being developed for postpartum depression. Sage is developing its
next generation modulators, including SAGE-217 and SAGE-718, with a
focus on acute and chronic CNS disorders.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160921006449/en/
